NEW ORLEANS -- Paramount Gold-Silver (TSX: PZG, Stock Forum) and Gold Standard Ventures (TSX: V.GSV, Stock Forum) are our top TCR choices for corporate events in the coming weeks.
GSV is one of our long-standing Nevada holdings and is coveted by several gold producers poring through Nevada portfolios. Corporate examinations of Gold Standard's gold and silver properties at Railroad and Pinon are happening all month, I believe.
As for the rapidly recovering TSX and TSXV small-caps, we put together informational scans for our choice gainers. It is behind a pay wall at thomcalandra.com -- for our TCR subscribers.
Here is what I can say.
On the price front for rapid gainers in the event the gold price, and platinum, and silver, commodity prices continue to drive higher, our TCR scans put Mexico-Nevada developer Paramount (PZG) at the top of the list, followed by both Asanko Gold (TSX: AKG, Stock Forum) and Platinum Group Metals (TSX: PTM, Stock Forum).
Our scan criteria [we are not technicians here at TCR] include recent buying by high-risk hedge funds, such as George Soros's network, along with plenty of trading liquidity from two exchanges: NY and Toronto.
We also look at beta levels that could indicate quick gains in the event of an overall metals rally and ensuing equities' lift. Each of those qualify.
On the Platinum Group Metals front, founder R. Michael Jones is still in South Africa, managing one fast-developing mine and one exploration project. I know the principals of each of these companies, and I own each of the equities, with the exception of Asanko Gold (Ghana).
Stellar-Diamonds is a name I rarely note here. It is a long-held personal holding after CEO Karl Smithson took me to Sierra Leone to see the Tonga diamond project there -- three or more years ago. Today's big-diamond report from the Guinea property, also in western Africa, is moving the AIM-listed shares. STEL in London is one of those microscopic 2-pence stocks with a gazillion shares out. Yet the market cap is just 10 million pounds, or approx. $16 million all in. Mr. Smithson is sending me several photos of the latest carat crop. I hope to see the Guinea project the next time Karl is over there -- sooner rather than later.
On the technology front, the TSX and TSXV exchanges this week are kicking into gear on speculative buying.
Please see thomcalandra.com and thomcalandra.com/free-blog for freebies.
BioCryst Pharma (NASDAQ: BCRX, Stock Forum) is one of two survivors this week in the Ebola equities arena. NewLink Genetics (NASDAQ: NLNK, Stock Forum) and its experimental vaccine look to be ready with a new compound for health care workers and those in Africa with the disease by January. BCRX shares continue to hold their gains. Everything else this week thus far is getting buried.
BioCryst is the developer of an Ebola treatment, not a vaccine. The American company is set up for a stream of events in the next two months: clinical and/or regulatory updates of influenza, Ebola, leukemia, angio-edema, and a quarterly report among them.
Several of our TCR subscribers are purchasing the November $13 call options for BCRX stock. They are high risk, high reward -- the options that is -- and expire November 13, 2014.
See our paying subscribers ($129 yearly) in New Orleans later this week. I will be meeting there at the yearly Investment Conference with Paramount's Chris Crupi, among about a dozen other execs -- and with the sci-team from Chuck Provini's solar-cell developer Natcore Technologies (TSX: V.NXT, Stock Forum)
THE CALANDRA REPORT: Subscribe
Now $129 yearly! My ass is on the line, too.
See: A thomcalandra.com home for our expanding TCR family.